STOCK TITAN

Pharvaris (PHVS) CMO reports 109 shares withheld for RSU tax obligations

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Pharvaris N.V. Chief Medical Officer Lu Peng reported a small share disposition tied to equity compensation. On the vesting of restricted stock units on June 11, 2026, 109 shares of common stock were withheld to cover tax withholding obligations at a fair market value of $31.51 per share. After this tax-withholding event, Lu Peng directly owns 65,748 shares of Pharvaris common stock, so the filing reflects routine administration of stock-based compensation rather than an open-market trade.

Positive

  • None.

Negative

  • None.
Insider Lu Peng
Role Chief Medical Officer
Type Security Shares Price Value
Tax Withholding Common Stock 109 $31.51 $3K
Holdings After Transaction: Common Stock — 65,748 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Shares withheld for taxes 109 shares Withheld to satisfy tax obligations on RSU vesting June 11, 2026
Fair market value per share $31.51 per share Value used for withheld shares on June 11, 2026
Shares owned after transaction 65,748 shares Direct Pharvaris common stock holdings after tax-withholding event
restricted stock units financial
"upon the vesting of restricted stock units on June 11, 2026"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
tax withholding obligations financial
"shares withheld to satisfy tax withholding obligations upon the vesting"
fair market value financial
"withheld on June 11, 2026 at a fair market value of $31.51"
The price a willing buyer and a willing seller would agree on for an asset or security when neither is under pressure and both have access to the same information. Think of it as the market’s neutral estimate of what something is worth, like the price two neighbors would settle on for a car after comparing similar listings. Investors care because fair market value guides buying and selling decisions, tax reporting, portfolio valuation, and how accurately company assets are reflected in financial statements.
Form 4 regulatory
"INSIDER FILING DATA (Form 4):"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lu Peng

(Last)(First)(Middle)
1 CRANBERRY HILL SUITE 400

(Street)
LEXINGTON MASSACHUSETTS 02421

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Pharvaris N.V. [ PHVS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Medical Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/11/2026F109(1)D$31.5165,748D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units on June 11, 2026. The shares were withheld on June 11, 2026 at a fair market value of $31.51 per share.
/s/ Marnus Nel, Attorney-in-Fact for Peng Lu06/15/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Pharvaris (PHVS) report for Lu Peng?

Pharvaris reported that Chief Medical Officer Lu Peng had 109 shares withheld to cover tax obligations when restricted stock units vested on June 11, 2026. This was a compensation-related withholding, not an open-market stock sale.

Was the Pharvaris (PHVS) Form 4 a stock sale by Lu Peng?

No, the Form 4 shows a tax-withholding disposition, not an open-market sale. Shares were withheld by Pharvaris to satisfy Lu Peng’s tax obligations upon RSU vesting at a fair market value of $31.51 per share.

How many Pharvaris (PHVS) shares were withheld for Lu Peng’s taxes?

A total of 109 Pharvaris common shares were withheld to satisfy Lu Peng’s tax withholding obligations on June 11, 2026, in connection with the vesting of restricted stock units granted as part of his compensation.

What is Lu Peng’s Pharvaris (PHVS) shareholding after this Form 4?

After the tax-withholding transaction, Lu Peng directly holds 65,748 Pharvaris common shares. The filing indicates his continuing equity stake following the RSU vesting and related withholding event disclosed for June 11, 2026.

What price per share did Pharvaris (PHVS) use for Lu Peng’s withheld shares?

The company used a fair market value of $31.51 per share for the 109 withheld shares. This value applied on June 11, 2026, when the restricted stock units vested and the tax withholding was processed.